Alzamend Neuro, Inc. (ALZN)
Nasdaq: ALZN · Pharmaceutical Preparations · Atlanta, GA · filing with the SEC since 2016
Who owns Alzamend Neuro, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
11
report now, of 14 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
Milton C. Ault, III
SCHEDULE 13D/A · filed Oct 7, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 8% in Oct 3, 2025
What ALZN reports owning in othersstakes of 5% or more, and other ties
Alzamend Neuro, Inc. reports no stake in another company in the record.
Insider tradesForm 4
11sales
5purchases
0sales on a scheduled plan
3people selling
$900,000sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 14 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Ault Milton C III | director | 10 | $1.0M | 0 | 5 | $300,000 |
| Horne William B. | director | 1 | $0 | 0 | 0 | $0 |
| Mcgrath Lynne Fahey | director | 1 | $0 | 0 | 0 | $0 |